Core Viewpoint - The document outlines the fundraising management system of Xinxiang Ruifeng New Materials Co., Ltd, emphasizing the importance of proper management and usage of raised funds to protect investors' interests and comply with relevant laws and regulations [1][2]. Fundraising Management Principles - The company must ensure that the use of raised funds aligns with the commitments made in the prospectus and cannot change the purpose of the funds without proper procedures [2][3]. - The board of directors is responsible for the management and use of raised funds, with oversight from the audit committee and sponsor institutions [2][3]. Fundraising Account Management - Raised funds must be stored in a designated special account, and any excess funds should also be managed within this account [8][9]. - The company must sign a tripartite supervision agreement with the sponsor and the bank holding the funds within one month of the funds being in place [3][4]. Fund Usage Regulations - The company is required to use the raised funds according to the investment plan disclosed in the issuance application documents and must disclose the actual usage of the funds accurately [12][13]. - The company is prohibited from using raised funds for high-risk investments, including financial investments and securities trading [13][14]. Monitoring and Reporting - The company must conduct a comprehensive review of the fundraising projects every six months and disclose any significant deviations from the planned investment amounts [16][17]. - Any changes in the use of raised funds must be approved by the board and disclosed promptly, including the reasons for the changes [30][31]. Handling Idle Funds - Temporarily idle funds can be used to supplement working capital only under strict conditions and must be returned to the special account within a specified timeframe [21][22]. - The company must disclose the situation regarding idle funds and their intended use within two trading days after board approval [22][23]. Excess Fund Management - The company must develop a plan for the use of excess funds, which should be allocated to ongoing and new projects or share buybacks [10][11]. - Any cash management of temporarily idle excess funds must be disclosed, ensuring it does not affect the normal operation of fundraising projects [11][12]. Compliance and Oversight - The finance department must maintain detailed records of the usage of raised funds, and internal audits should be conducted quarterly [40][41]. - Independent directors can hire external auditors to verify the actual use of funds if discrepancies are found [42][43].

Core Viewpoint - The document outlines the fundraising management system of Shandong Weiming Biological Pharmaceutical Co., Ltd, emphasizing the proper storage, usage, and management of raised funds to enhance efficiency and protect investors' rights [1][2]. Group 1: Fundraising Management Principles - The company must establish a detailed plan for the use of raised funds, ensuring transparency and compliance with national laws and regulations [2][4]. - The board of directors is responsible for the effective implementation of the fundraising management system [1][2]. - Funds raised must be stored in a dedicated account and cannot be used for non-designated purposes [7][8]. Group 2: Fund Usage Regulations - Raised funds should be used strictly for the purposes disclosed in the prospectus or other public documents, and any changes must be approved by the shareholders [9][11]. - The company is prohibited from using raised funds for high-risk investments or providing financial assistance to others [11][12]. - Any changes in the investment projects must undergo a feasibility analysis and be disclosed promptly [14][15]. Group 3: Oversight and Reporting - The company must maintain detailed records of the usage of raised funds and undergo regular audits to ensure compliance [33][34]. - The board must report on the status of fundraising and usage at least semi-annually, including any discrepancies in investment progress [15][16]. - Independent financial advisors or sponsors are required to conduct regular checks and report any irregularities [17][18].

国金证券股份有限公司 关于江西沐邦高科股份有限公司 未能按期归还临时补充流动资金的闲置募集资金的核查意见 国金证券股份有限公司（以下简称"国金证券"或"保荐人"）作为江西沐邦高 科股份有限公司（以下简称"沐邦高科"或"公司" ）向特定对象发行股票的保荐人， 根据《证券发行上市保荐业务管理办法》 《上海证券交易所股票上市规则》 《上市公司 募集资金监管规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 等相关法律、法规和规范性文件的规定，对沐邦高科未能按期归还临时补充流动资金 的闲置募集资金的情况进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证监会出具的《关于同意江西沐邦高科股份有限公司向特定对象发行 股票注册的批复》（证监许可〔2023〕2928 号），公司向特定对象发行人民币普通股 扣除不含增值税发行费用人民币 16,138,375.95 元后，实际募集资金净额为人民币 款人民币 1,405,301,480.90 元已全部到账。大华会计师事务所（特殊普通合伙）对募 集资金到位情况进行了审验并出具了《江西沐邦高科股份有限公司发行人民币普通 股（A 股）91,007,017 股后实收 ...

Fundraising Overview - The company raised a total of RMB 799,999,551.04 by issuing 13,331,104 shares, with a net amount available for use of RMB 785,238,867.98 after deducting issuance costs of RMB 14,760,683.06 [1] - As of June 30, 2025, the total amount of funds raised was RMB 799,999,551.04, with RMB 286,401,559.99 already utilized [1] Fund Utilization - The company has invested RMB 270,845,820.74 in fundraising projects, with RMB 173,379,023.89 being the amount spent in the current period [1] - The company temporarily idled RMB 330,000,000.00 for cash management investments, including RMB 300,000,000.00 in structured deposits [1][6] Fund Management - The company has established a special account storage system for the management of raised funds and signed tripartite and quadripartite supervision agreements with relevant banks and sponsors [2][3] - As of June 30, 2025, the remaining balance of the raised funds was RMB 7,223,132.13 [3] Cash Management - The company approved the use of up to RMB 60,000,000.00 of idle funds for temporary working capital, but as of June 30, 2025, no such funds had been utilized [4] - The company also approved the use of up to RMB 40,000,000.00 of idle funds for cash management, with a focus on high-security and high-liquidity products [4] Project Updates - The company has extended the timeline for the "High-Speed Communication Connector Component Production Project" to December 2026, with the addition of a new implementation entity [8] - There have been no instances of using excess funds for working capital or repaying bank loans as of June 30, 2025 [7]

Meeting Overview - The third supervisory board meeting of Dongguan Dingtong Precision Technology Co., Ltd. was held on July 30, 2025, with all three supervisors present [1][2] - The meeting was chaired by Xu Hao and complied with relevant laws, regulations, and the company's articles of association [1] Financial Report Approval - The supervisory board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's financial status and operational performance without any false records or misleading statements [1][2] Fund Usage Report - The board approved the special report on the storage and usage of raised funds for the first half of 2025, confirming compliance with regulations and that the funds were stored in a dedicated account and used for specified purposes [2][3] Profit Distribution Plan - The board approved the profit distribution plan for the first half of 2025, allowing for a cash dividend of 2.00 RMB per 10 shares (tax included), based on a total share capital of 139,201,726 shares as of June 30, 2025, amounting to a total cash dividend of 27,840,345.20 RMB [3][4] - The plan considers the company's profitability and future funding needs, ensuring no harm to the interests of the company and its shareholders, especially minority shareholders [3]

募集资金使用管理制度 益丰大药房连锁股份有限公司 第一章 总则 第一条 为了规范益丰大药房连锁股份有限公司（以下简称"公司"）募集资 金的管理，提高募集资金的使用效率，依据《中华人民共和国公司法》《中华人 民共和国证券法》《上海证券交易所股票上市规则》《上市公司募集资金监管规 则》等规定和《益丰大药房连锁股份有限公司章程》等有关规定，制定本制度。 第二条 本制度所称募集资金是指：公司通过公开发行证券（包括首次公开 发行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换公司债券、 发行权证等）以及非公开发行证券向投资者募集并用于特定用途的资金。 第三条 募集资金的使用应以合法、合规、追求效益为原则，做到周密计划、 精打细算、规范运作，正确把握投资时机和投资进度，正确处理好投资金额、投 入产出、投资效益之间的关系，控制投资风险。 第四条 公司董事会负责建立健全公司募集资金管理制度，并确保该制度的 有效实施募集资金投资项目通过公司的子公司或公司控制的其他企业实施的，适 用本制度。 第二章 募集资金专户存储 第五条 募集资金应存放于董事会批准设立的专项账户（以下简称"募集资金 专户"）集中管理。募集资金专户不 ...

经中国证券监督管理委员会核发的《关于同意中兰环保科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2021]2504号）同意注册，并经深圳 证券交易所同意，公司首次公开发行人民币普通股（A）股共计2,480.00万股， 发行价格为9.96元/股，募集资金总额为人民币247,008,000.00元，扣除发行费用 （不含税）人民币49,143,378.53元后，募集资金净额为人民币197,864,621.47元。 立信会计师事务所（特殊普通合伙）对公司首次公开发行股票募集资金到位情 况进行了审验，并于2021年9月10日出具了《中兰环保科技股份有限公司公开发 行人民币普通股（A股）2,480万股后实收股本的验资报告》（信会师报字[2021] 第Z110529号）。 （二） 募集资金的实际使用及结余情况 项目名称 金额（元） 募集资金总额 247,008,000.00 减：扣除已支付的发行费用 49,143,378.53 减：使用募集资金投入（承诺） 166,593,368.49 减：补充流动资金（永久） 减：补充流动资金（暂时） 减：现金管理 减：对外投资 减：发生手续费 13,258.25 加：利息收入 ...

上海硅产业集团股份有限公司募集资金使用管理制度 上海硅产业集团股份有限公司 募集资金使用管理制度 第一章 总 则 第一条 为了规范上海硅产业集团股份有限公司（以下简称"公司"）募集资 金的管理和使用，切实保护投资者的权益，根据《中华人民共和国公司法》《中 华人民共和国证券法》 《上市公司募集资金监管规则》 《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》等有关法律、法规、规范性文件和《上 海硅产业集团股份有限公司章程》（以下简称"《公司章程》"）的要求，结合公 司的实际情况，特制定本制度。 本制度所指募集资金是指公司通过向不特定对象发行股票或者其他具有股 权性质的证券（包括首次公开发行股票、配股、增发、发行可转换公司债券、发 行分离交易的可转换公司债券等）以及向特定对象发行证券向投资者募集并用于 特定用途的资金，但不包括公司实施股权激励计划募集的资金。 第二条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能力和创新能力。公司募集资金应当投资于科技创 新领域，促进新质生产力发展。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000582 证券简称：北部湾港 公告编号：2025050 债券代码：127039 债券简称：北港转债 北部湾港股份有限公司 北部湾港股份有限公司（以下简称公司）第十届董事会第十六次会议于2025年7月29日（星期二）09:00 在南宁市良庆区体强路12号北部湾航运中心B座15楼1526会议室以现场结合通讯的方式召开。本次会议 通知及有关材料已于2025年7月26日通过电子邮件的方式送达各位董事、监事和高级管理人员。本次会 议应出席董事8人，实际出席董事8人，其中董事洪峻、胡文晟以通讯方式出席会议并表决。会议由董事 长刘胜友主持，公司监事及高级管理人员列席了会议。本次会议的召集、召开符合法律法规、规范性文 件及《公司章程》的规定，合法有效。 二、董事会会议审议通过以下议案 （一）《关于审议总经理辞职的议案》 公司董事、总经理周延因工作岗位变动，提出辞去董事、总经理及董事会战略委员会委员职务。根据 《中华人民共和国公司法》（以下简称《公司法》）《公司章程》等相关规定，董事辞职自辞职报告送 达董事会时生效，同时经公司董事会审议，同意周延辞去公司总经理职务 ...

Core Viewpoint - The company has decided to postpone the implementation of the "Annual Production of 7,000 Tons of Diphenylmethane (DBM) Intelligent Manufacturing Technological Transformation and Expansion Project" based on a comprehensive assessment of market demand and current operational conditions, despite the project still being deemed necessary and feasible [7][32][34]. Group 1: Company Overview - The company is Shandong Jianbang New Materials Co., Ltd., with the stock code 603285 and the abbreviation "Jianbang Shares" [3]. - The company held its second board meeting on July 29, 2025, with all seven directors present, ensuring compliance with legal and regulatory requirements [4][5]. Group 2: Financial Data - The company raised a total of RMB 746 million through its initial public offering, with a net amount of RMB 663.45 million after deducting issuance costs [25][39]. - As of June 30, 2025, the company reported its fundraising usage and balance, indicating effective management of the raised funds [67]. Group 3: Project Updates - The company conducted a re-evaluation of the DBM project, concluding that while the market outlook remains stable, the current production line can meet demand, leading to the decision to delay the project [28][32][34]. - The company has been optimizing its existing production processes, achieving a production increase of 51.05% year-on-year in 2024 for the DBM/SBM workshop [31]. Group 4: Fund Management - The company plans to use temporarily idle funds for cash management, with a maximum amount of RMB 40 million allocated for investments in low-risk, high-liquidity products [62][63]. - The company has established strict protocols for managing and utilizing the raised funds, ensuring compliance with relevant regulations [40][41].